Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Oct 11;11(4):535–550. doi: 10.1002/cpdd.1023

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 The Authors. Clinical Pharmacology in Drug Development published by Wiley Periodicals LLC on behalf of American College of Clinical Pharmacology

This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Blood sampling and intervention schedule on treatment day. Blood sampling time points are specified in hours relating to the time point of BF‐200 ALA application. Time point 0 is defined as the start of the application of BF‐200 ALA. (A) MUsT‐1 was designed as a fixed‐sequence trial, comparing placebo and BF‐200 ALA sequentially in the same cohort with an identical intervention protocol. Patients were treated on the face or forehead with 2 g BF‐200 ALA (156 mg ALA) and illuminated after 3 hours of incubation with up to 2 lamps. (B) MUsT‐2 was designed as an open‐label trial, patients were treated on either the face/scalp or body periphery with 6 g BF‐200 ALA (468 mg ALA) and illuminated after 3 hours of incubation with up to 2 lamps. ALA, 5‐aminolevulinic acid; MUsT, maximal usage pharmacokinetic trial.